The Clinical Value of Lipid Abnormalities in Cervical Cancer

Anyang Li  
Wenzhou Medical University

Luhui Wang  
Wenzhou Medical University

Mengya Jin  
Wenzhou Medical University

Yueyao Shou  
Wenzhou Medical University

Feiyun Zheng  
Wenzhou Medical University First Affiliated Hospital: The First Affiliated Hospital of Wenzhou Medical University

Haiyan Zhu (zhuhaiyandoc@sina.com)  
Tongji Medical University: Tongji Medical College  https://orcid.org/0000-0002-1030-4601

Research

Keywords: Cervical cancer, lipid profile, triglyceride, cholesterol, Prognosis

DOI: https://doi.org/10.21203/rs.3.rs-118805/v1

License: ☺️ ☀️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** To describe the characteristic of plasma lipid profile among cervical cancer and further evaluate the prognostic significance of lipid levels in cervical cancer.

**Methods:** We retrospectively reviewed 1,713 patients with cervical cancer in our hospital. Preoperative plasma lipid profile, including cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL), of 1,713 cervical cancer patients were compared with 10,397 healthy women. Then, we evaluated the impact of lipids on overall survival (OS) and recurrence-free survival (RFS) in cervical cancer using univariate and multivariate Cox model.

**Results:** While plasma TC, TG and LDL were significantly higher, HDL was lower in patients with cervical cancer as compared with healthy women. TG was identified as independent predictors for RFS, and OS among patients with cervical cancer. Further stratified by age, patients with higher TG showed a significantly worse RFS and OS compared with those with lower TG among patients ≥ 50 years old, but not among <50 years old.

**Conclusion:** Cervical cancer was associated with a disordered lipid profile. Hypertriglyceridemia was an independent poor prognostic indicator for cervical cancer, especially for elder patients. Strengthening lipid management may be beneficial for improving postoperative OS and RFS in patients with cervical cancer.

1. Introduction

Cervical cancer is the most common gynecologic malignancy with an estimated 596,847 new cases and 311,365 deaths in 2018 worldwide[1]. High-risk subtypes of the human papillomavirus (HPV) infection has been well established as the main cause for cervical carcinoma. In the past decade, the use of screening programs and HPV vaccination program has dramatically reduced the incidence of cervical cancer in developed countries. However, these diseases remain a heavy health burden and a major public health problem in the developing world because of the high incidence and poor prognosis of recurrent disease. Therefore, it is imperative to identify some simple and valuable predictor that could identify high-risk cervical cancer patients, poor progression and prognosis, further facilitating novel treatment strategy and improving clinical outcome.

A large body of evidence has shown a relationship between lipid abnormalities and cancer initiation[2]. Lipids crucially contribute to cell proliferation and tumorigenesis, due to its influence on chemical-energy storage, cellular signaling, cell membranes, and cell-cell interactions[2]. Pre-clinical studies have revealed the ability of adipocytes providing energy for rapid cancer growth and metastasis[3]. A positive correlation was found between serum triglycerides (TG) and risk of endometrial cancer[4]. High levels of total cholesterol (TC) and low density lipoprotein (LDL) increased colorectal cancer risk[5]. Hypertriglyceridemia increased the risk of prostate cancer and promoted the aggressiveness of these disease[6, 7]. With regard to cervical cancer, triglyceride was reported elevated among cervical cancer patients in an India population[8]. However, no significant difference in any lipid parameters was detected.
between cervical cancer group and uterine leiomyomas group in a study by Sun et al[9]. Thus, the alterations of plasma lipid profiles in cervical cancer remains a matter of controversy.

Recently, lipid parameters were described as a prognostic factor in various cancers, with contradictory findings. While increased levels of LDL were reported as a negative prognosis in nasopharyngeal carcinoma[10], higher preoperative LDL was related to an improved 5-year RFS of ovarian cancer[11]. Besides, high density lipoprotein (HDL) was a favorable prognostic indicators of lung cancer and breast cancer [12, 13]. So far, the impact of lipid abnormalities in cervical cancer has been poorly investigated. In the current study, we first evaluated the correlation between lipid parameters and cervical cancer, then further explored the prognostic value of preoperative lipid profile in a large population of cervical cancer patients treated with radical hysterectomy, and thus, identified a reliable and convenient predictor.

2. Materials And Methods

2.1 Study population

This study included 1,713 patients with pathologically confirmed uterine cervical carcinoma, who underwent radical hysterectomy between January 2008 and December 2018 at the First Affiliated Hospital of Wenzhou Medical University, China. The following exclusion Criteria was used: (1) Women who received any drugs that impacted lipid metabolism; (2) Patients with chronic diseases that effected lipid levels (i.e., diabetes); 3) Patients received any treatments before serum collection. Information mentioned above was obtained from the electronic medical records. Besides, the control group included 10,397 healthy women. This study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University and informed consent was signed by the patients before taking part in this study. A detailed review of patient history, general physical examination, pelvic examination (including bimanual pelvic and rectal examinations), preoperative laboratory (plasma lipid profiles, and SCC-Ag), pathological data (metastasis, stage, and differentiation) of all patients were collected from electronic medical records and reviewed. Detailed clinical data were collected within one week before operation. Preoperative plasma levels of HDL, LDL, TC, TG, and serum squamous cell carcinoma antigen (SCC-Ag) were measured in early morning before surgical operation and immediately measured using a Hitachi 7600-020 automatic biochemical analyzer with the kinetic method [11]. Body mass index (BMI) was calculated as body-weight(kg)/height(m)^2.

All of 1,713 cervical cancer patients were classified as high-risk, intermediate-risk, and low-risk after postoperative pathological evaluation. High-risk patients defined as the presence of tumor involvement of the parametria, positive margins, or lymph node metastases [14]. Intermediate risk factors included depth of invasion, lymphovascular space invasion, and tumor size [15]. Patients without high and intermediate risk factors are defined as low-risk.

Besides, we collected age, BMI, plasma levels of HDL, LDL, TC, TG from 10,397 healthy women as control. Given that lipid levels were affected by confounders such as age and BMI, we matched the
healthy women group and the cervical cancer group with age, with every 10 years as a subgroup. Then, by randomly matching the healthy control group and the cancer group with a ratio of 2:1, we obtained 3,426 healthy women. We then controlled the potential confounders (age and BMI) by regression analysis and analyzed the difference of lipid levels between healthy group and cancer group.

Follow-up examinations were performed every 3 months in the first 2 years, and then every 6 months for the next 3 years and every 1 year thereafter. Pelvic examination, cytology, the serum concentration of SCC-Ag, and imaging studies including Computed Tomography, Magnetic Resonance Imaging, or Positron Emission Tomography-Computed Tomography, were performed during routine follow up.

The last follow-up date was July 15, 2019. The end points of this study were overall survival (OS) and recurrence-free survival (RFS). Overall survival was determined from the date of surgery to death or last follow-up. Recurrence-free survival (RFS) was calculated from the date of surgery to the tumor recurrence or distant metastasis.

2.2 Statistical analysis

Continuous data were presented as median (Q1-Q3) or mean ± standard deviation based on their distribution. and then difference between groups were tested using the Wilcoxon rank-sum test or a standard t test. Categorical data were analyzed using Fisher’s exact test or χ² test. The Kaplan-Meier method was used to calculate survival estimates for OS and RFS. Univariate and multivariate Cox regression analyses were used to evaluate the associations between clinical covariates and survival. A two-tailed \( P < 0.05 \) was considered statistically significant. Analyses were performed using R(version 3.3).

3. Results

3.1 Characteristics of cervical cancer

Clinical and pathologic characteristics of cervical cancer were summarized in Table 1. This study included 1,713 cervical cancer patients. The median age at diagnosis was 52 years (range: 22–82 years) and the median BMI was 23.24 (19.95, 26.53). The most common histological type was squamous cell carcinoma (85.9%), followed by adenocarcinoma (9.0%). All of patients were diagnosed with FIGO stage I-II. Tumor sizes in 221 patients (22.9%) were \( \geq 4 \) cm, 560 (58.3%) were 2-4cm, and 181 (18.8%) were < 2 cm. In addition, 274 patients showed lymph node metastasis, 342 cases were lymphovascular space invasion and 40 patients were parametrial involvement. Based on pathology after radical hysterectomy, there were 319 (18.6%) patients with high risk factors, 643 (37.5%) patients with intermediate risk factors.
Table 1
The baseline patients’ characteristics

| Parameter                  | No.(%)       | Q2(Q1, Q3)    |
|----------------------------|--------------|---------------|
| Age (years)                | 1713         | 52(45, 60)    |
| Tumor subtype              |              |               |
| Squamous                   | 1472 (85.9%) |               |
| Adenocarcinoma             | 154(9.0%)    |               |
| Other                      | 87(5.1%)     |               |
| FIGO stage                 |              |               |
| I                          | 987(57.6)    |               |
| II                         | 726(42.4)    |               |
| Tumor size                 |              |               |
| ≥ 4 cm                     | 221 (23.1%)  |               |
| 2-4cm                      | 560(58.2%)   |               |
| <2 cm                      | 181(18.8%)   |               |
| Differentiation            |              |               |
| I-II                       | 1344(93.0%)  |               |
| III                        | 101(7.0%)    |               |
| Lymph node Metastasis      |              |               |
| No                         | 1397(83.6%)  |               |
| Yes                        | 274(16.4%)   |               |
| Lymphovascular space invasion |          |               |
| No                         | 1328(79.5%)  |               |
| Yes                        | 342(20.5%)   |               |
| Parametrial involvement    |              |               |
| No                         | 1665(97.7%)  |               |
| Yes                        | 40(2.3%)     |               |

Abbreviations: No. = number of patients; SCC-Ag = serum squamous cell carcinoma antigen; TC = total cholesterol; TG = triglycerides; HDL = high-density lipoprotein; LDL = low-density lipoprotein
| Parameter            | No.(%) | Q2(Q1, Q3) |
|----------------------|--------|------------|
| < 1/3                | 573(33.6%) |            |
| ≥ 1/3 < 2/3          | 348(20.4%) |            |
| ≥ 2/3                | 783(46.0%) |            |
| SCC(Pre-O) (U/mL)    | 1434   | 1.4(0.9, 3.4) |
| TC (mmol/L)          | 1502   | 5.08(4.41, 5.84) |
| TG (mmol/L)          | 1500   | 1.49(1.03, 2.24) |
| HDL (mmol/L)         | 1457   | 1.26(1.08, 1.48) |
| LDL (mmol/L)         | 1455   | 2.92(2.42, 3.52) |

Abbreviations: No. = number of patients; SCC-Ag = serum squamous cell carcinoma antigen; TC = total cholesterol; TG = triglycerides; HDL = high-density lipoprotein; LDL = low-density lipoprotein

3.2 Lipid profile in healthy women and patients with cervical cancer

In 1,713 patients with cervical cancer, the median preoperative levels of TC, TG, LDL and HDL were 5.08(4.41, 5.84), 1.49(1.03, 2.24), 2.92(2.42, 3.52), and 1.26(1.08, 1.48) mmol/L, respectively. Figure 1 showed the comparisons of plasma lipid levels between healthy women and patients with cervical cancer. While plasma levels of TC, TG, and LDL were significantly higher, plasma HDL levels were significantly lower among patients with cervical cancer as compared with healthy women (Fig. 1A).

Given that age may influence lipid levels, all the individuals were further divided into young (< 50 years) and old groups (≥ 50 years). Similarly, patients with cervical cancer showed higher TC, TG, and LDL levels, and lower HDL as compared with healthy women both in young and old groups (Fig. 1B). Subsequently, we matched the healthy group and the cancer group with age, with every 10 years as a subgroup. Then, by randomly matching the healthy group and the cancer group with a ratio of 2: 1, we obtained 3,426 healthy women. Patients with cervical cancer showed higher TC, TG, and LDL levels, and lower HDL levels than healthy women (Supplementary Fig. 1). The difference of lipid levels, including TC, TG, LDL and HDL, between healthy group and cancer group remained statistically significant after further adjustment for age and BMI (P < 0.001, P = 0.001, P < 0.001, P = 0.008, respectively). Thus, compared with healthy women, patients with cervical cancer were coupled to a disordered lipid profile characterized by higher TG, TC and LDL levels, and lower HDL levels.

3.3 Lipid Profile Levels and survival

Following-up was available for 1,499 cervical cancer patients. With a median follow-up of 4.76 (2.40, 8.21) years, 156 patients (10.41%) suffered relapse and 102 patients (6.80%) deceased.
Initially, univariate analyses were employed to depict the prognostic value of clinicopathological features among patients with cervical cancer. As expected, the factors that were statistically significant in predicting poor RFS as well as OS were positive lymph node metastasis, parametrial involvement, late FIGO stage, positive lymphovascular space invasion, deeper infiltration depth, large tumor size and increased pre-operative level of SCC-Ag (Table 2).

Table 2
Univariate Cox regression analysis of clinical characteristics regarding RFS and OS

| Parameter                        | Classify                      | RFS        | P     | OS         | P     |
|----------------------------------|-------------------------------|------------|-------|------------|-------|
|                                  |                               | HR (95%CI) |       | HR (95%CI) |       |
| Age                              | ≤50 year vs. ≤50 year         | 1.17(0.84-1.62) | 0.355 | 1.75(1.15-2.66) | 0.008* |
| Tumor size                       | ≥ 2 cm vs. 1 cm               | 1.85(0.99-3.47) | 0.056 | 2.98(1.07-8.26) | 0.036* |
|                                  | ≥ 4 cm vs. 4 cm               | 1.8(1.16-2.82) | 0.009* | 1.81(1.01-3.26) | 0.048* |
| FIGO stage                       | II vs. I                      | 2(1.44-2.79) | < 0.001* | 2.23(1.48-3.36) | < 0.001* |
| Lymph node Metastasis            | Yes vs. No                    | 3.75(2.69-5.24) | < 0.001* | 4.21(2.81-6.32) | < 0.001* |
| Lymphovascular space invasion    | Yes vs. No                    | 2.36(1.67-3.33) | < 0.001* | 2.16(1.41-3.3) | < 0.001* |
| Differentiation                  | III vs. I-II                  | 0.44(0.16-1.18) | 0.101 | 0.5(0.16-1.57) | 0.235 |
| Tumor subtype                    | Adenocarcinoma vs. Squamous   | 1.28(0.74-2.24) | 0.378 | 1.51(0.8-2.84) | 0.205 |
| Parametrial involvement          | Yes vs. No                    | 3.96(2.19-7.16) | < 0.001* | 4.55(2.21-9.39) | < 0.001* |
| Depth of cervical stromal invasion | ≥ 1/3 vs. <1/3               | 3.01(1.94-4.68) | < 0.001* | 2.78(1.65-4.7) | < 0.001* |
| SCC-Ag                           | > 1.5 ug/L vs. ≤ 1.5 ug/L     | 2.02(1.43-2.85) | < 0.001* | 1.9(1.22-2.96) | 0.004* |

Abbreviations: RFS = recurrence-free survival; OS = overall survival; SCC-Ag = serum squamous cell carcinoma antigen

*: P < 0.05
Next, we explored the prognostic value of the lipid profile among patients with cervical cancer. Cut-off was determined according to the medium lipid levels of 1,499 cervical cancer patients. Patients were divided into “low” and “high” according to the comparisons between lipid profile levels with established cut-offs. Table 3 showed the RFS and OS of the patients included in the study according to TC, TG, LDL and HDL levels. As shown in Table 3, patients with high TG levels had a significantly worse RFS than those with low TG levels both in univariate and multivariate Cox model. However, null association was detected between TC/LDL/HDL and RFS of cervical cancer.

Table 3
Univariate Cox regression analysis and Multivariate Cox regression analysis of lipid profile regarding Recurrence-Free Survival and Overall survival

| Parameter | Univariate analysis | Multivariate analysis# |
|-----------|---------------------|------------------------|
|           | HR (95%CI)          | P          | HR (95%CI) | P          |
| RFS       | 1.24 (1.00-1.30)    | 0.058      |            |            |
| TC        | 1.15 (1.04–1.26)    | 0.005*     | 1.12 (1.02–1.31) | 0.033*   |
| TG        | 0.75 (0.43–1.29)    | 0.293      |            |            |
| HDL       | 1.02 (0.86–1.17)    | 0.964      |            |            |
| LDL       | 1.02 (0.86–1.17)    | 0.964      |            |            |
| OS        | 1.21 (1.03–1.42)    | 0.024*     | 1.12 (0.83–1.50) | 0.462   |
| TC        | 1.18 (1.06–1.31)    | 0.002*     | 1.23 (1.08–1.40) | 0.025*   |
| TG        | 0.86 (0.44–1.69)    | 0.67       |            |            |
| HDL       | 1.04 (0.88–1.23)    | 0.624      |            |            |
| LDL       | 1.24 (1.00-1.30)    | 0.058      |            |            |

Abbreviations: RFS: recurrence-free survival; OS: overall survival; TC = total cholesterol; TG = triglycerides; HDL = high-density lipoprotein; LDL = low-density lipoprotein

#: Adjusted for age, FIGO stage, lymph node metastasis, parametrial involvement, lymphovascular space invasion, infiltration depth, tumor size and increased pre-operative level of SCC-Ag.

*: P < 0.05

With regard to OS, the univariate analysis revealed that increased TC and TG levels were significant correlation with a poor OS of cervical cancer. Further multivariate analysis showed increased levels of TG related to a significantly unfavorable OS of cervical cancer. Higher TC group had a trend towards higher HRs for OS compared with the lower group; however, P-values were 0.462. Nevertheless, HDL and LDL levels have no effect on OS (HR: 0.86; 95%CI: 0.44–1.69; P: 0.67; HR: 1.04; 95%CI: 0.88–1.23; P: 0.624,
respectively) (Table 3). The Kaplan–Meier curves for RFS and OS of the two groups (high TG levels vs low TG levels) were further illustrated in Fig. 2.

Since lipid levels were commonly associated with age, all the individuals were further divided into two groups according to age (< 50 years vs. ≥ 50 years). Stratified by age, interestingly, no significant association was detected between lipid profile and RFS/OS of cervical cancer among patients < 50 years old. Nevertheless, patients with higher TG had a significantly worse RFS and OS than those with lower TG among patients ≥ 50 years old (Table 4).

Table 4
Univariate Cox regression analysis of lipid profile regarding Recurrence-Free Survival and Overall survival stratified by age

| Parameter | RFS | OS |
|-----------|-----|----|
|           | HR (95%CI) | P  | HR (95%CI) | P  |
| Young group (< 50 years) |       |    |       |    |
| TC        | 1.14(0.89–1.47) | 0.306 | 1.24(0.88–1.76) | 0.218 |
| TG        | 1.02(0.80–1.30) | 0.863 | 1.14(0.85–1.53) | 0.380 |
| HDL       | 1.31(0.62–2.76) | 0.485 | 1.34(0.46–3.88) | 0.595 |
| LDL       | 0.99(0.79–1.24) | 0.913 | 1.03(0.80–1.33) | 0.808 |
| Old groups (≥ 50 years) |       |    |       |    |
| TC        | 1.13(0.95–1.35) | 0.169 | 1.12(0.92–1.37) | 0.252 |
| TG        | 1.17(1.05–1.29) | 0.003* | 1.15(1.02–1.30) | 0.026* |
| HDL       | 0.46(0.21–1.00) | 0.050 | 0.71(0.30–1.66) | 0.426 |
| LDL       | 1.01(0.80–1.28) | 0.930 | 1.01(0.78–1.32) | 0.929 |

Abbreviations: RFS: recurrence-free survival; OS: overall survival; TC = total cholesterol; TG = triglycerides; HDL = high-density lipoprotein; LDL = low-density lipoprotein

*: *P* < 0.05

Cervical cancer patients with high-risk factors showed worse prognosis as comparing with patients with intermediate-risk or low-risk factor, we further analyzed patients with high-risk factors. As shown in Fig. 3, higher level of TG was an independent poor prognostic factor among cervical cancer patients with high risk (Fig. 3).

4. Discussion
In this study, we explored the clinical signification of lipids profile among cervical cancer patients, and made several important discoveries. Firstly, we comprehensively investigated the difference in serum lipid levels between healthy women and patients with cervical cancer using a relative large number of population, and demonstrated that TC/TG/LDL were elevated, and HDL were decreased in patients with cervical cancer. These results suggest dyslipidemia could be correlation with cervical cancer. Secondly, to our knowledge, this is the first report to evaluate the prognostic value of lipids profile in cervical cancer. Our study showed that hyperlipidemia was an independent prognostic factor for both RFS and OS among patients with cervical cancer.

Lipids are essential components of cell membranes, lipid metabolism essentially contributes to tumor cell bioenergetics and biomass formation[16]. Cholesterol and triglycerides are the two main lipids in plasma[17]. LDL and HDL are lipoproteins responsible for cholesterol transportation. While the LDL lead cholesterol to the cells and facilitate the deposition of fat in the vessel, the HDL is on the opposite promotes the removal of excess cholesterol[17]. Epidemiological studies, despite being controversial, reported the correlation between plasma triglyceride levels and the risk for cancer. Higher levels of triglyceride was associated with increased risk of lung, thyroid cancer, renal cancer, prostate cancer, gynecological cancer in a large cohort study in Austria[18]. Similarly, triglycerides were reported to increase the risk for cervix cancer in females, and colon and thyroid cancer in males in a cohort of 22,946 Icelanders[19]. Conversely, lower triglyceride (< 1.70 mmol/L) was related to an evaluated cancer risk in Chinese type 2 diabetes mellitus patients[20]. Our observation of higher lipid profile in cervical cancer was similar to a previous cohort study among Icelanders, which regarded triglycerides as a positive risk factor for cervix cancer[19]. Further evidence for a relationship with triglyceride comes from India[8]. Raju et al reported TG was elevated in cervical cancer as comparing to healthy control[8]. Therefore, cervical cancer are coupled to a disordered lipid profile characterized by higher TG, TC and LDL levels, and lower HDL levels. Dyslipidemia could be associated with cervical cancer.

Our current study further explored the prognostic value of hyperlipidemia at diagnosis in cervical cancer. We provided first evidence that higher plasma triglyceride levels correlated to a worse RFS as well as OS among patients with cervical cancer. This observation was consistent with previous studies in prostate cancer and breast cancer. Elevated serum triglycerides increased the risk of prostate cancer recurrence[21]. Hypertriglycerideridemia was correlation with a decreased 5-year OS among patients with triple negative breast cancer[22]. In a recently published, monocentric, retrospective study, Vernieri et al reported higher plasma triglyceride levels correlated with lower progression-free survival in everolimus-treated patients with advanced pancreatic neuroendocrine tumors[23]. These findings, coupled with evidence that adipocytes provided energy for rapid cancer growth and metastasis in vivo and in vitro[3], indicate that increased utilize of extracellular lipids, or their de novo synthesis, could increase the recurrence risk and result into poor clinical outcomes among cervical cancer. Therefore, we recommend lipid management for patients with cervical cancer, especially those have hyperlipidemia. Accordingly, lipid profile was recommended routinely evaluated during follow-up.
Stratification by age revealed a negative association between hypertriglyceridemia and prognosis in patients ≥ 50 years old rather than in patients < 50 years old, suggesting hypertriglyceridemia was associated with poor outcomes of cervical cancer patients, especially for elder patients. Sub-analysis for cervical cancer patients with high-risk factor, showed that higher level of TG was an independent poor prognostic factor for this population. These sub-analysis further supported preoperative lipid profile as a promising prognostic predictor in cervical cancer by controlling the confounding data.

Our study has some limitations. As a retrospective study, it was limited availability of collecting the change of lipid profile during follow-up. This is because serum lipid profile was not routinely evaluated in all patients during follow-up. A prospective randomized study evaluating the survival benefits of controlling lipids in primary cervical cancer is warranted.

5. Conclusions

In conclusion, a disordered lipid profile characterized by higher TG, TC and LDL levels, and lower HDL levels could be associated with cervical cancer. TG exerted unfavorable influence either on RFS or on OS of cervical cancer. Hypertriglyceridemia was an independent negative prognostic predictor for cervical cancer. This simple and routinely tested parameters may be a convenient prognostic candidate for cervical cancer in clinic. Strengthening lipid management may be beneficial for improving postoperative OS and RFS in patients with cervical cancer.

Abbreviations

HPV: human papillomavirus; TG: triglycerides; TC: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; SCC-Ag: serum squamous cell carcinoma antigen; OS: overall survival; RFS: recurrence-free survival; BMI: body mass index.

Declarations

– Acknowledgments

We would like to thank all doctors, nurses, patients, and their family members for their kindness to support our study.

– Consent for publication

The authors declare that they agree to publish.

– Ethics approval and consent to participate

This study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University and informed consent was signed by the patients before taking part in this study.

– Competing interests
The authors declare that they have no competing interests.

—Availability of data and materials

Available under request.

—Authors’ contributions:

HZ and FZ conception and design the study; AL, WW, LW acquisition of data, AL, MJ and YS analysis of data; AL drafting the manuscript; HZ revising this manuscript. All authors read and approved the final manuscript.

—Funding information:

This work was supported by grants from the Natural Science Foundation of Zhejiang Province (No. LY19H160021) and Technology Development Funds of Wenzhou City (Y20180014).

References

1. F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin 68 (2018), 394-424.

2. F. Perrotti, C. Rosa, I. Cicalini, P. Sacchetta, P. Del Bocco, D. Genovesi and D. Pieragostino, Advances in Lipidomics for Cancer Biomarkers Discovery, Int J Mol Sci 17 (2016).

3. K.M. Nieman, H.A. Kenny, C.V. Penicka, A. Ladanyi, R. Buell-Gutbrod, M.R. Zillhardt, I.L. Romero, M.S. Carey, G.B. Mills, G.S. Hotamisligil, S.D. Yamada, M.E. Peter, K. Gwin and E. Lengyel, Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth, Nat Med 17 (2011), 1498-503.

4. K. Lindemann, L.J. Vatten, M. Ellstrom-Engh and A. Eskild, Serum lipids and endometrial cancer risk: results from the HUNT-II study, Int J Cancer 124 (2009), 2938-41.

5. C. Agnoli, S. Grioni, S. Sieri, C. Sacerdote, P. Vineis, R. Tumino, M.C. Giurdanella, V. Pala, A. Mattiello, P. Chiodini, L. Iacoviello, A. De Curtis, L. Cattaneo, F.J. van Duijnhoven, S. Panico and V. Krogh, Colorectal cancer risk and dyslipidemia: a case-cohort study nested in an Italian multicentre cohort, Cancer Epidemiol 38 (2014), 144-51.

6. L. Wuermli, M. Joerger, S. Henz, H.P. Schmid, W.F. Riesen, G. Thomas, W. Krek, T. Cerny and S. Gillessen, Hypertriglyceridermia as a possible risk factor for prostate cancer, Prostate Cancer Prostatic Dis 8 (2005), 316-20.

7. R. Arthur, H. Moller, H. Garmo, L. Holmberg, P. Stattin, H. Malmstrom, M. Lambe, N. Hammar, G. Walldius, D. Robinson, I. Jungner and M.V. Hemelrijck, Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories, Cancer Med 5 (2016), 1307-18.
8. K. Raju, S.S. Punnayanapalya, N. Mariyappa, S.M. Eshwarappa, C. Anjaneya and L.J. Kai, Significance of the plasma lipid profile in cases of carcinoma of cervix: a tertiary hospital based study, *Asian Pac J Cancer Prev* **15** (2014), 3779-84.

9. Y. Sun, H. Meng, Y. Jin, X. Shi, Y. Wu, D. Fan, X. Wang, X. Jia and H. Dai, Serum lipid profile in gynecologic tumors: a retrospective clinical study of 1,550 patients, *Eur J Gynaecol Oncol* **37** (2016), 348-52.

10. Q. Tang, Q.Y. Hu, Y.F. Piao and Y.H. Hua, Correlation between pretreatment serum LDL-cholesterol levels and prognosis in nasopharyngeal carcinoma patients, *Onco Targets Ther* **9** (2016), 2585-91.

11. F. Zhu, X. Xu, B. Shi, L. Zeng, L. Wang, X. Wu and H. Zhu, The positive predictive value of low-density lipoprotein for recurrence-free survival in ovarian cancer, *Int J Gynaecol Obstet* **143** (2018), 232-238.

12. P.D. Chi, W. Liu, H. Chen, J.P. Zhang, Y. Lin, X. Zheng, W. Liu and S. Dai, High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma, *PLoS One* **9** (2014), e91080.

13. Y. Fan, X. Ding, J. Wang, F. Ma, P. Yuan, Q. Li, P. Zhang and B. Xu, Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs, *Int J Biol Markers* **30** (2015), e200-7.

14. W.A. Peters, 3rd, P.Y. Liu, R.J. Barrett, 2nd, R.J. Stock, B.J. Monk, J.S. Berek, L. Souhami, P. Grigsby, W. Gordon, Jr. and D.S. Alberts, Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix, *J Clin Oncol* **18** (2000), 1606-13.

15. M. Rotman, A. Sedlis, M.R. Piedmonte, B. Bundy, S.S. Lentz, L.I. Muderspach and R.J. Zaino, A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study, *Int J Radiat Oncol Biol Phys* **65** (2006), 169-76.

16. C. Vernieri, S. Casola, M. Foiani, F. Pietrantonio, F. de Braud and V. Longo, Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions, *Cancer Discov* **6** (2016), 1315-1333.

17. M.J. Chapman, H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Boren, A.L. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, P. Lesnik, L. Masana, B.G. Nordestgaard, K.K. Ray, Z. Reiner, M.R. Taskinen, L. Tokgozoglu, A. Tybjaerg-Hansen, G.F. Watts and P. European Atherosclerosis Society Consensus, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, *Eur Heart J* **32** (2011), 1345-61.

18. H. Ulmer, W. Borena, K. Rapp, J. Klenk, A. Strasak, G. Diem, H. Concin and G. Nagel, Serum triglyceride concentrations and cancer risk in a large cohort study in Austria, *Br J Cancer* **101** (2009), 1202-6.

19. H. Tulinius, N. Sigfusson, H. Sigvaldason, K. Bjarnadottir and L. Tryggvadottir, Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders, *Cancer Epidemiol Biomarkers Prev* **6** (1997), 863-73.
20. X. Yang, R.C. Ma, W.Y. So, L.W. Yu, A.P. Kong, G.T. Ko, G. Xu, R. Ozaki, P.C. Tong and J.C. Chan, Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry, *Cancer* **117** (2011), 862-71.

21. E.H. Allott, L.E. Howard, M.R. Cooperberg, C.J. Kane, W.J. Aronson, M.K. Terris, C.L. Amling and S.J. Freedland, Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database, *Cancer Epidemiol Biomarkers Prev* **23** (2014), 2349-56.

22. T. Lofterod, E.S. Mortensen, H. Nalwoga, T. Wilsgaard, H. Frydenberg, T. Risberg, A.E. Eggen, A. McTiernan, S. Aziz, E.A. Wist, A. Stensvold, J.B. Reitan, L.A. Akslen and I. Thune, Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes, *BMC Cancer* **18** (2018), 654.

23. C. Vernieri, S. Pusceddu, G. Fuca, P. Indelicato, G. Centonze, L. Castagnoli, E. Ferrari, A. Ajazi, S. Pupa, S. Casola, M. Foiani, V. Mazzaferro, G. Pruneri, M. Milione and F. de Braud, Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs), *Int J Cancer* **144** (2019), 1704-1712.

**Figures**
Figure 1

(A) Comparison of plasma lipid profile levels between healthy women and cervical cancer patients. (B) Comparison of plasma lipid profile levels between healthy women and cervical cancer patients stratified by age. Normal: healthy women.
Figure 2

Kaplan-Meier curves for recurrence-free survival (A) and overall survival (B) of patients with cervical cancer according to TG levels. Patients were stratified into high and low groups according to the cut-off value of 1.49 mmol/L. High TG levels are associated with a poor RFS as well as OS of cervical cancer. P values were estimated using log-rank test.
Figure 3

Univariate analyses of recurrence-free survival (A) and overall survival (B) of cervical cancer patients with high-risk factor. Multivariate analyses of recurrence-free survival (C) and overall survival (D) of cervical cancer patients with high-risk factor. P values were estimated using log-rank test.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• FigureS1.tif